Dr Larsen graduated from the University of Auckland School of Medicine in 1999. She trained in Internal Medicine and then Dermatology in Auckland. Following this, Dr Larsen undertook sub-specialised Dermatology training at the University of Texas Southwestern Medical Center in Dallas, Texas, USA. This involved a year and a half Dermatopathology fellowship, specifically the pathologic diagnosis of skin conditions. Dr Larsen then completed a one-year Procedural Dermatology fellowship, accredited by the American College for Graduate Medical Education. The fellowship encompassed thorough training in Mohs micrographic skin cancer surgery and cosmetic dermatology. Fiona Larsen Dermatology is a comprehensive centre for all skin concerns. Dr Larsen's areas of special interest include the prevention of skin cancer and skin damage, skin cancer treatment, Mohs micrographic surgery, medical aesthetics and cosmetic treatments. Her mission is to deliver personalised service along with highly skilled, comprehensive care. Mohs surgery is a unique form of skin cancer surgery developed by Frederick Mohs, MD, in the 1940s. Since then, the technique has been refined and advanced. Today, this specialised procedure is performed by highly trained Specialist Dermatologists with skill in skin cancer diagnosis, surgical removal, microscopic analysis and facial reconstruction. The excised skin cancer tissue is processed rapidly onto microscope slides to allow examination of the entire edge and deep part of the specimen. The Specialist Dermatologist then meticulously examines these slides under the microscope. If cancer cells are seen, an additional tissue layer is removed only in areas where the cancer is still present, thereby preserving as much of the surrounding healthy skin as possible. Once the cancer has been completely removed, the Specialist Dermatologist will repair the wound to minimise scarring and ensure the best possible cosmetic result. Cure rates for localised skin cancers treated with Mohs micrographic surgery are higher than for any other type of treatment – approximately 99 per cent for new skin cancers and 95 per cent for difficult recurrent skin cancers.